Literature DB >> 25660391

SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype.

E Bugiardini1, I Rivolta2, A Binda2, A Soriano Caminero3, F Cirillo4, A Cinti5, R Giovannoni5, A Botta6, R Cardani7, M P Wicklund3, G Meola8.   

Abstract

In myotonic dystrophy type 2 (DM2), an association has been reported between early and severe myotonia and recessive chloride channel (CLCN1) mutations. No DM2 cases have been described with sodium channel gene (SCN4A) mutations. The aim is to describe a DM2 patient with severe and early onset myotonia and co-occurrence of a novel missense mutation in SNC4A. A 26-year-old patient complaining of hand cramps and difficulty relaxing her hands after activity was evaluated at our department. Neurophysiology and genetic analysis for DM1, DM2, CLCN1 and SCN4A mutations were performed. Genetic testing was positive for DM2 (2650 CCTG repeat) and for a variant c.215C>T (p.Pro72Leu) in the SCN4A gene. The variation affects the cytoplasmic N terminus domain of Nav1.4, where mutations have never been reported. The biophysical properties of the mutant Nav1.4 channels were evaluated by whole-cell voltage-clamp analysis of heterologously expressed mutant channel in tsA201 cells. Electrophysiological studies of the P72L variant showed a hyperpolarizing shift (-5 mV) of the voltage dependence of activation that may increase cell excitability. This case suggests that SCN4A mutations may enhance the myotonic phenotype of DM2 patients and should be screened for atypical cases with severe myotonia.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Myotonia; Myotonic dystrophy type 2; N-terminus; SCN4A

Mesh:

Substances:

Year:  2015        PMID: 25660391     DOI: 10.1016/j.nmd.2015.01.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  19 in total

1.  Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2.

Authors:  Federica Montagnese; Stefania Mondello; Stephan Wenninger; Wolfram Kress; Benedikt Schoser
Journal:  J Neurol       Date:  2017-10-30       Impact factor: 4.849

Review 2.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

Review 3.  Guidelines on clinical presentation and management of nondystrophic myotonias.

Authors:  Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2020-05-27       Impact factor: 3.217

Review 4.  Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.

Authors:  Giovanni Meola; Fiammetta Biasini; Rea Valaperta; Elena Costa; Rosanna Cardani
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

5.  Translating genetic and functional data into clinical practice: a series of 223 families with myotonia.

Authors:  Karen Suetterlin; Emma Matthews; Richa Sud; Samuel McCall; Doreen Fialho; James Burge; Dipa Jayaseelan; Andrea Haworth; Mary G Sweeney; Dimitri M Kullmann; Stephanie Schorge; Michael G Hanna; Roope Männikkö
Journal:  Brain       Date:  2022-04-18       Impact factor: 15.255

6.  Coexistence of CLCN1 and SCN4A mutations in one family suffering from myotonia.

Authors:  Lorenzo Maggi; Sabrina Ravaglia; Alessandro Farinato; Raffaella Brugnoni; Concetta Altamura; Paola Imbrici; Diana Conte Camerino; Alessandro Padovani; Renato Mantegazza; Pia Bernasconi; Jean-François Desaphy; Massimiliano Filosto
Journal:  Neurogenetics       Date:  2017-10-09       Impact factor: 2.660

Review 7.  Skeletal Muscle Channelopathies.

Authors:  Lauren Phillips; Jaya R Trivedi
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 8.  Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.

Authors:  Samantha LoRusso; Benjamin Weiner; W David Arnold
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

9.  Novel SCN5A p.Val1667Asp Missense Variant Segregation and Characterization in a Family with Severe Brugada Syndrome and Multiple Sudden Deaths.

Authors:  Michelle M Monasky; Emanuele Micaglio; Giuseppe Ciconte; Ilaria Rivolta; Valeria Borrelli; Andrea Ghiroldi; Sara D'Imperio; Anna Binda; Dario Melgari; Sara Benedetti; Predrag Mitrovic; Luigi Anastasia; Valerio Mecarocci; Žarko Ćalović; Giorgio Casari; Carlo Pappone
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

10.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.